市場調査レポート

商品コード

1193319

関節痛注射市場：注射タイプ別、関節別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Joint Pain Injections Market By Injection Type, By Joint Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年11月01日 | 発行: Allied Market Research

| ページ情報: 英文 310 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 560,989円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 900,412円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,508,544円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

関節痛注射の世界市場は、2021年に62億7191万米ドル、2031年には131億7631万米ドルに達し、2022年から2031年までのCAGRは7.7％を記録すると予測されています。

関節痛注射は、損傷した関節組織に直接薬剤を塗布する非外科的な処置のことを指します。関節痛は、関節炎やその種類、関節の過去の損傷、筋肉の使い過ぎ、うつ病、不安、ストレス、肥満など様々な理由に関連する関節に生じる不快感として定義されています。さらに、インターロイキン阻害剤は、関節の痛みや炎症を和らげるために、麻酔薬とコルチコステロイドを組み合わせた最も一般的な注射の一つです。

関節炎財団によると、2022年に発生した数値の時点で、関節炎と診断された成人は約6000万人で、成人の4人に1人がこれらのタイプの関節炎のいずれかを患っていると言われています。このように、座りっぱなしの生活や肥満の増加、運動による怪我、ストレスなどにより、あらゆる年齢層で関節炎の発症が増加していることが、関節痛注射の大規模な販売につながると考えられます。

さらに、製薬会社による最先端の治療技術の導入、患者による正確な治療オプションの需要の増加、新興経済諸国における高収入の確保などにより、関節痛注射の市場は成長すると予想されています。

関節炎財団は、16歳未満の子どもに発症する炎症性疾患は若年性関節炎と呼ばれ、米国では30万人近くの子どもや10代の若者が罹患していると述べていますが、オーストラリア政府は、関節炎の負担に対処するための国家努力を導くことを目的として「The National Strategic Action Plan for Arthritis」を発表しています。このように、政府によるさらなる取り組みや資金提供は、市場の成長を後押しすることになるでしょう。

概要
- 市場規模および予測
インターロイキンインヒビター
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
ヒアルロン酸注入剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第5章関節痛注射市場：関節別

概要
- 市場規模および予測
膝関節と足関節
- 主な市場動向、成長要因、機会
- 市場規模および予測：地域別
- 市場分析：国別
股関節
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
肩・肘関節
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
背骨のファセット関節
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第6章関節痛注射市場：流通チャネル別

概要
- 市場規模および予測
病院薬局
- 主な市場動向、成長要因と機会
- 市場規模・予測：地域別
- 市場分析：国別
- 病院薬局の関節痛注射市場：タイプ別
  - 公立病院薬局の市場規模及び予測：地域別
  - 民間病院薬局市場規模推移・予測：地域別
ドラッグストア・小売薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
オンラインプロバイダー
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章関節痛注射市場：地域別

概要
- 市場規模・予測
北米
- 主要動向と機会
- 北米市場規模・予測：注射タイプ別
- 北米市場規模・予測：関節別
- 北米市場規模・予測：流通チャネル別
  - 北米病院薬局の関節痛注射市場：タイプ別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主な動向と機会
- 欧州市場規模・予測：注射タイプ別
- 欧州市場規模・予測：関節別
- 欧州市場規模・予測：流通チャネル別
  - 欧州病院薬局向け関節痛注射市場：タイプ別
- 欧州市場規模・予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他の欧州地域
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：注射タイプ別
- アジア太平洋地域の市場規模・予測：関節別
- アジア太平洋地域の市場規模・予測：流通チャネル別
  - アジア太平洋地域の病院薬局向け関節痛注射市場：タイプ別
- アジア太平洋地域の市場規模・予測：国別
  - 日本
  - 中国
  - オーストラリア
  - インド
  - 韓国
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：注射タイプ別
- LAMEAの市場規模・予測：関節別
- LAMEAの市場規模・予測：流通チャネル別
  - LAMEA病院薬局の関節痛注射市場：タイプ別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ共和国
  - LAMEAの残りの地域

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

Abbvie Inc
Anika Therapeutics
Bioventus
Eli Lilly and Company
Ferring Pharmaceuticals Inc.
PACIRA BIOSCIENCES（Flexion Therapeutics, Inc.）
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceuticals
Zimmer Biomet

図表

LIST OF TABLES

TABLE 1. GLOBAL JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 2. JOINT PAIN INJECTIONS MARKET, FOR INTERLEUKIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. JOINT PAIN INJECTIONS MARKET FOR INTERLEUKIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. JOINT PAIN INJECTIONS MARKET, FOR HYALURONIC ACID INJECTIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. JOINT PAIN INJECTIONS MARKET FOR HYALURONIC ACID INJECTIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. JOINT PAIN INJECTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. JOINT PAIN INJECTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. GLOBAL JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 9. JOINT PAIN INJECTIONS MARKET, FOR KNEE AND ANKLE, BY REGION, 2021-2031 ($MILLION)
TABLE 10. JOINT PAIN INJECTIONS MARKET FOR KNEE AND ANKLE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. JOINT PAIN INJECTIONS MARKET, FOR HIP JOINT, BY REGION, 2021-2031 ($MILLION)
TABLE 12. JOINT PAIN INJECTIONS MARKET FOR HIP JOINT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. JOINT PAIN INJECTIONS MARKET, FOR SHOULDER AND ELBOW, BY REGION, 2021-2031 ($MILLION)
TABLE 14. JOINT PAIN INJECTIONS MARKET FOR SHOULDER AND ELBOW, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. JOINT PAIN INJECTIONS MARKET, FOR FACET JOINTS OF THE SPINE, BY REGION, 2021-2031 ($MILLION)
TABLE 16. JOINT PAIN INJECTIONS MARKET FOR FACET JOINTS OF THE SPINE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. JOINT PAIN INJECTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 18. JOINT PAIN INJECTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. GLOBAL JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 20. JOINT PAIN INJECTIONS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 21. JOINT PAIN INJECTIONS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. GLOBAL HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 23. JOINT PAIN INJECTIONS MARKET, FOR PUBLIC HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 24. JOINT PAIN INJECTIONS MARKET, FOR PRIVATE HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 25. JOINT PAIN INJECTIONS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 26. JOINT PAIN INJECTIONS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. JOINT PAIN INJECTIONS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 28. JOINT PAIN INJECTIONS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. JOINT PAIN INJECTIONS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. U.S. JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 36. U.S. JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 37. U.S. JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 38. CANADA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 39. CANADA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 40. CANADA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. MEXICO JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 42. MEXICO JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 43. MEXICO JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. EUROPE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 45. EUROPE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 46. EUROPE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. EUROPE HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. EUROPE JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 49. GERMANY JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 50. GERMANY JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 51. GERMANY JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. FRANCE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 53. FRANCE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 54. FRANCE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. UK JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 56. UK JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 57. UK JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. ITALY JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 59. ITALY JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 60. ITALY JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. SPAIN JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 62. SPAIN JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 63. SPAIN JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 65. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 66. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 70. ASIA-PACIFIC HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 71. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 72. JAPAN JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 73. JAPAN JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 74. JAPAN JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. CHINA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 76. CHINA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 77. CHINA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. INDIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 82. INDIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 83. INDIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 85. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 86. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. LAMEA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 91. LAMEA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 92. LAMEA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 93. LAMEA HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 94. LAMEA JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 95. BRAZIL JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 96. BRAZIL JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 97. BRAZIL JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 100. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 103. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 106. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 107.ABBVIE INC: COMPANY SNAPSHOT
TABLE 108.ABBVIE INC: OPERATING SEGMENTS
TABLE 109.ABBVIE INC: PRODUCT PORTFOLIO
TABLE 110.ABBVIE INC: NET SALES,
TABLE 111.ABBVIE INC: KEY STRATERGIES
TABLE 112.ANIKA THERAPEUTICS: COMPANY SNAPSHOT
TABLE 113.ANIKA THERAPEUTICS: OPERATING SEGMENTS
TABLE 114.ANIKA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 115.ANIKA THERAPEUTICS: NET SALES,
TABLE 116.ANIKA THERAPEUTICS: KEY STRATERGIES
TABLE 117.BIOVENTUS: COMPANY SNAPSHOT
TABLE 118.BIOVENTUS: OPERATING SEGMENTS
TABLE 119.BIOVENTUS: PRODUCT PORTFOLIO
TABLE 120.BIOVENTUS: NET SALES,
TABLE 121.BIOVENTUS: KEY STRATERGIES
TABLE 122.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 123.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 124.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 125.ELI LILLY AND COMPANY: NET SALES,
TABLE 126.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 127.FERRING PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 128.FERRING PHARMACEUTICALS INC.: OPERATING SEGMENTS
TABLE 129.FERRING PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 130.FERRING PHARMACEUTICALS INC.: NET SALES,
TABLE 131.FERRING PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 132.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): COMPANY SNAPSHOT
TABLE 133.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): OPERATING SEGMENTS
TABLE 134.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): PRODUCT PORTFOLIO
TABLE 135.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): NET SALES,
TABLE 136.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): KEY STRATERGIES
TABLE 137.PFIZER INC.: COMPANY SNAPSHOT
TABLE 138.PFIZER INC.: OPERATING SEGMENTS
TABLE 139.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 140.PFIZER INC.: NET SALES,
TABLE 141.PFIZER INC.: KEY STRATERGIES
TABLE 142.SANOFI S.A.: COMPANY SNAPSHOT
TABLE 143.SANOFI S.A.: OPERATING SEGMENTS
TABLE 144.SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 145.SANOFI S.A.: NET SALES,
TABLE 146.SANOFI S.A.: KEY STRATERGIES
TABLE 147.TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 148.TEVA PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 149.TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 150.TEVA PHARMACEUTICALS: NET SALES,
TABLE 151.TEVA PHARMACEUTICALS: KEY STRATERGIES
TABLE 152.ZIMMER BIOMET: COMPANY SNAPSHOT
TABLE 153.ZIMMER BIOMET: OPERATING SEGMENTS
TABLE 154.ZIMMER BIOMET: PRODUCT PORTFOLIO
TABLE 155.ZIMMER BIOMET: NET SALES,
TABLE 156.ZIMMER BIOMET: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.JOINT PAIN INJECTIONS MARKET SEGMENTATION
FIGURE 2.JOINT PAIN INJECTIONS MARKET,2021-2031
FIGURE 3.JOINT PAIN INJECTIONS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.JOINT PAIN INJECTIONS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.PATENT ANALYSIS BY COMPANY
FIGURE 13.PATENT ANALYSIS BY COUNTRY
FIGURE 14.JOINT PAIN INJECTIONS MARKET,BY INJECTION TYPE,2021(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INTERLEUKIN INHIBITORS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HYALURONIC ACID INJECTIONS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 18.JOINT PAIN INJECTIONS MARKET,BY JOINT TYPE,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF KNEE AND ANKLE JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HIP JOINT JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF SHOULDER AND ELBOW JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF FACET JOINTS OF THE SPINE JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHERS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 24.JOINT PAIN INJECTIONS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 28.JOINT PAIN INJECTIONS MARKET BY REGION,2021
FIGURE 29.U.S. JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 30.CANADA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 31.MEXICO JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 32.GERMANY JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 33.FRANCE JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 34.UK JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 35.ITALY JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 36.SPAIN JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 37.REST OF EUROPE JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 38.JAPAN JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 39.CHINA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 40.AUSTRALIA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 41.INDIA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 42.SOUTH KOREA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 43.REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 44.BRAZIL JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 45.SAUDI ARABIA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 46.SOUTH AFRICA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 47.REST OF LAMEA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 52.COMPETITIVE DASHBOARD
FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 54.ABBVIE INC.: NET SALES ,($MILLION)
FIGURE 55.ANIKA THERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 56.BIOVENTUS.: NET SALES ,($MILLION)
FIGURE 57.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
FIGURE 58.FERRING PHARMACEUTICALS INC..: NET SALES ,($MILLION)
FIGURE 59.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.).: NET SALES ,($MILLION)
FIGURE 60.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 61.SANOFI S.A..: NET SALES ,($MILLION)
FIGURE 62.TEVA PHARMACEUTICALS.: NET SALES ,($MILLION)
FIGURE 63.ZIMMER BIOMET.: NET SALES ,($MILLION)

Product Code: A31459

The global joint pain injections market was valued at $6,271.91 million in 2021, and is projected to reach $13,176.31 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.

Joint pain injections refer to the non-surgical procedures that involves application of the medication directly to damage joint tissue. Joint pain is defined as the discomfort caused into the joints which is associated with the various reasons including the arthritis and its different kinds, the previous injuries to a joint, overuse of the muscle, depression, anxiety, stress, and obesity. Furthermore, interleukin inhibitors are one of the most common types of therapeutic injections that include an anesthetic agent combined with a corticosteroid to relieve joint pain and inflammation.

According to the Arthritis Foundation, as of the numbers generated in 2022 there are about 60 million adults who have been diagnosed with arthritis and 1 in 4 adults have one of these types of arthritis. This rise in incidence of arthritis among all age groups owing to a sedentary lifestyle, rise in obesity, injuries due to physical activities and stress, will lead to the sales of the joint pain injection on a large scale.

Furthermore, the joint pain injections market is anticipated to grow by the introduction of numerous cutting-edge treatment technologies by the pharmaceutical companies, an increase in the demand for accurate treatment options by the patients, and the availability of high income in the developed economies.

Arthritis Foundation also states that, the inflammatory and rheumatic diseases that develops in children under the age of 16 is known to be juvenile arthritis, which affects nearly 300,000 kids and teens in the U.S. However, the government of Australia has published 'The National Strategic Action Plan for Arthritis' that aims to guide national efforts to address the burden of arthritis. Thus, such more initiatives and funding provided by the government will boost the growth of the market.

In addition, the rise in investment for research and development of the advanced and precise treatment options by public and private players in the market with an aim to improve health care infrastructure, due to the rise in the prevalence of the arthritis, along with rise in the obesity and geriatric patients are the key factors for the expansion of the joint pain injections market. For instance, the U.S. FDA approval for the second indication for Skyrizi (risankizumab-rzaa) to treat adults with active psoriatic arthritis that can be administered with a single injection four times a year.

However, the market is expected to be significantly constrained in the near future by factors such as lack of awareness about these injections in developing nations, their expensive price, and lack of reimbursement policies that effects the adoption of the products in the emerging countries. However, the key market players are developing more efficient treatment options which includes the single injection therapy and plasma matrix therapy, which will provide lucrative opportunities during the forecast period.

The joint pain injections market is segmented on the basis of injection type, by joint type, by distribution channel and region. By injection type, it is divided into interleukin inhibitors, hyaluronic acid injections and others. On the basis of joint type, the market is segmented into knee & ankle, hip joint, shoulder & elbow, facet joints of the spine and others. According to the distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies and online providers. Further, the hospital pharmacies segment is divided into public hospital pharmacies and private hospital pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in this report include Abbvie Inc., Anika Therapeutics Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pacira Biosciences (Flexion Therapeutics, Inc.), Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Zimmer Biomet and among others.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the joint pain injections market analysis from 2021 to 2031 to identify the prevailing joint pain injections market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the joint pain injections market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global joint pain injections market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Injection Type

Interleukin Inhibitors
Hyaluronic Acid Injections
Others

By Joint Type

Knee and Ankle
Hip Joint
Shoulder and Elbow
Facet Joints of the Spine
Others

By Distribution Channel

Hospital Pharmacies
- Type
- Public Hospital Pharmacies
- Private Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbvie Inc
- Anika Therapeutics
- Bioventus
- Eli Lilly and Company
- Ferring Pharmaceuticals Inc.
- PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceuticals
- Zimmer Biomet

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape

CHAPTER 4: JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Interleukin Inhibitors
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Hyaluronic Acid Injections
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Others
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country

CHAPTER 5: JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Knee and Ankle
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Hip Joint
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Shoulder and Elbow
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
5.5 Facet Joints of the Spine
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
5.6 Others
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country

CHAPTER 6: JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospital Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.2.4 Hospital Pharmacies Joint Pain Injections Market by Type
  - 6.2.4.1 Public Hospital Pharmacies Market size and forecast, by region
  - 6.2.4.2 Private Hospital Pharmacies Market size and forecast, by region
6.3 Drug Stores and Retail Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Online Providers
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: JOINT PAIN INJECTIONS MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Injection Type
- 7.2.3 North America Market size and forecast, by Joint Type
- 7.2.4 North America Market size and forecast, by Distribution Channel
  - 7.2.4.1 North America Hospital Pharmacies Joint Pain Injections Market by Type
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Injection Type
  - 7.2.5.1.2 Market size and forecast, by Joint Type
  - 7.2.5.1.3 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Injection Type
  - 7.2.5.2.2 Market size and forecast, by Joint Type
  - 7.2.5.2.3 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Injection Type
  - 7.2.5.3.2 Market size and forecast, by Joint Type
  - 7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Injection Type
- 7.3.3 Europe Market size and forecast, by Joint Type
- 7.3.4 Europe Market size and forecast, by Distribution Channel
  - 7.3.4.1 Europe Hospital Pharmacies Joint Pain Injections Market by Type
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Injection Type
  - 7.3.5.1.2 Market size and forecast, by Joint Type
  - 7.3.5.1.3 Market size and forecast, by Distribution Channel
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Injection Type
  - 7.3.5.2.2 Market size and forecast, by Joint Type
  - 7.3.5.2.3 Market size and forecast, by Distribution Channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Injection Type
  - 7.3.5.3.2 Market size and forecast, by Joint Type
  - 7.3.5.3.3 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Injection Type
  - 7.3.5.4.2 Market size and forecast, by Joint Type
  - 7.3.5.4.3 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Injection Type
  - 7.3.5.5.2 Market size and forecast, by Joint Type
  - 7.3.5.5.3 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Injection Type
  - 7.3.5.6.2 Market size and forecast, by Joint Type
  - 7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Injection Type
- 7.4.3 Asia-Pacific Market size and forecast, by Joint Type
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
  - 7.4.4.1 Asia-Pacific Hospital Pharmacies Joint Pain Injections Market by Type
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Injection Type
  - 7.4.5.1.2 Market size and forecast, by Joint Type
  - 7.4.5.1.3 Market size and forecast, by Distribution Channel
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Injection Type
  - 7.4.5.2.2 Market size and forecast, by Joint Type
  - 7.4.5.2.3 Market size and forecast, by Distribution Channel
  - 7.4.5.3 Australia
  - 7.4.5.3.1 Market size and forecast, by Injection Type
  - 7.4.5.3.2 Market size and forecast, by Joint Type
  - 7.4.5.3.3 Market size and forecast, by Distribution Channel
  - 7.4.5.4 India
  - 7.4.5.4.1 Market size and forecast, by Injection Type
  - 7.4.5.4.2 Market size and forecast, by Joint Type
  - 7.4.5.4.3 Market size and forecast, by Distribution Channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Injection Type
  - 7.4.5.5.2 Market size and forecast, by Joint Type
  - 7.4.5.5.3 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Injection Type
  - 7.4.5.6.2 Market size and forecast, by Joint Type
  - 7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Injection Type
- 7.5.3 LAMEA Market size and forecast, by Joint Type
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
  - 7.5.4.1 LAMEA Hospital Pharmacies Joint Pain Injections Market by Type
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Injection Type
  - 7.5.5.1.2 Market size and forecast, by Joint Type
  - 7.5.5.1.3 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Injection Type
  - 7.5.5.2.2 Market size and forecast, by Joint Type
  - 7.5.5.2.3 Market size and forecast, by Distribution Channel
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Injection Type
  - 7.5.5.3.2 Market size and forecast, by Joint Type
  - 7.5.5.3.3 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Injection Type
  - 7.5.5.4.2 Market size and forecast, by Joint Type
  - 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Abbvie Inc
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Anika Therapeutics
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Bioventus
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Eli Lilly and Company
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Ferring Pharmaceuticals Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Pfizer Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Sanofi S.A.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Teva Pharmaceuticals
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Zimmer Biomet
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments

関節痛注射市場：注射タイプ別、関節別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Joint Pain Injections Market By Injection Type, By Joint Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章関節痛注射市場：注射タイプ別

第5章関節痛注射市場：関節別

第6章関節痛注射市場：流通チャネル別

第7章関節痛注射市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE

CHAPTER 5: JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE

CHAPTER 6: JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: JOINT PAIN INJECTIONS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

関節痛注射市場：注射タイプ別、関節別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Joint Pain Injections Market By Injection Type, By Joint Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 関節痛注射市場：注射タイプ別

第5章 関節痛注射市場：関節別

第6章 関節痛注射市場：流通チャネル別

第7章 関節痛注射市場：地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE

CHAPTER 5: JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE

CHAPTER 6: JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: JOINT PAIN INJECTIONS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章関節痛注射市場：注射タイプ別

第5章関節痛注射市場：関節別

第6章関節痛注射市場：流通チャネル別

第7章関節痛注射市場：地域別

第8章企業情勢

第9章企業プロファイル